Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Brain Behav · 2019 · PMC6749475 · PMID 31368669

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Two studies in patients with early‐stage hATTR polyneuropathy—Fx‐005 ( clinicaltrials.gov identifier: NCT00409175 ) and Fx‐006 ( clinicaltrials.gov identifier: NCT00791492 )—demonstrated less neurologic deterioration with tafamidis 20 mg once daily compared with placebo but did not reach statistical significance (Coelho, Maia, et al., 2013 ; Coelho et al., 2012 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.